Zai Lab Limited (ZLAB) Q4 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call summary and Q&A indicate strong product development, strategic market positioning, and potential for growth, especially with new launches like KarXT and expansion of VYVGART. The company shows disciplined financial management and a focus on profitability. However, some uncertainties in full-year guidance and market dynamics temper the outlook slightly. Overall, the sentiment leans positive with potential for stock appreciation.

Key Financial Performance

Full Year Revenue $460.2 million, representing 15% year-over-year growth. Reasons for growth include steady progress across the commercial portfolio, strong contributions from XACDURO and NUZYRA, and broader market coverage and increased penetration for NUZYRA.

Fourth Quarter Revenue $127.6 million, a 17% year-over-year increase. Growth was driven by strong contributions from XACDURO and NUZYRA, with XACDURO benefiting from strong patient demand and expanding hospital adoption, though supply constraints limited full realization of demand.

R&D Expenses Declined 6% year-over-year for the full year, driven by lower personnel compensation costs. However, increased in the fourth quarter due to fast progression of global clinical trials.

SG&A Expenses Decreased 12% year-over-year in the fourth quarter and 7% for the full year. The decline was mainly due to strategic resource optimization and reduction in general and administrative expenses.

Loss from Operations Improved 19% for the full year to $229.4 million and improved 25% when adjusted to exclude noncash expenses. This improvement reflects financial discipline and strategic resource optimization.

Cash Position Ended the quarter with $790 million, indicating a strong cash position.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

Zoci: Advanced from IND to global Phase III in less than 2 years. Potential U.S. approval by 2028. Demonstrated 80% objective response rate in brain metastases and favorable safety profile. Plans to initiate first-line pivotal trial in small cell lung cancer and additional combination regimens by year-end.

ZL-6201: Internally discovered LRRC15-targeting ADC. Received U.S. IND clearance and initiated global Phase I study.

ZL-1503: IL-13/IL-31 receptor alpha bispecific antibody for atopic dermatitis. Global Phase I/Ib study enrolling well with first-in-human data expected later this year.

China Business: Full year revenue grew 15% year-on-year. Commercial profitability continues to improve despite challenging macro environment.

Global Market: Zoci's addressable market in small cell lung cancer and neuroendocrine carcinomas estimated to exceed $9 billion globally.

NRDL Renewals: Successfully completed renewals for key products, strengthening long-term commercial portfolio.

Portfolio Optimization: Divested noncore assets and regions to reallocate resources toward higher priority growth opportunities and improve operational efficiency.

Business Development: Entered targeted collaborations to explore novel combination strategies in small cell lung cancer and strengthened oncology platform with MUC17/CD3 T-cell engager.

Financial Discipline: Improved operating leverage with R&D and SG&A expenses declining as a percentage of revenue. Loss from operations improved 19% for the full year.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Challenging macro and operating environment in China: The company acknowledges a challenging macro and operating environment in China, which could impact the stability and growth of its regional business.

Pricing dynamics and evolving competition for VYVGART: The near-term growth of VYVGART is expected to be influenced by pricing pressures and increasing competition, which could affect revenue generation.

Supply constraints for XACDURO: Supply constraints during the year limited the full realization of underlying demand for XACDURO, potentially impacting revenue and market share.

Volume-based procurement dynamics for ZEJULA: Variability in early-year performance for ZEJULA is expected due to volume-based procurement dynamics and seasonality, which could affect revenue stability.

Regulatory and approval timelines: The company faces risks related to regulatory and approval timelines for key pipeline assets, such as zoci and elegrobart, which are critical for future growth.

Dependence on clinical trial outcomes: The success of the company's pipeline is heavily dependent on clinical trial outcomes, which carry inherent risks of failure or delays.

Economic uncertainties: Economic uncertainties could impact the company's financial performance and operational stability, particularly in its key markets.

Operational efficiency and resource allocation: Efforts to optimize resources and improve operational efficiency may face challenges, potentially affecting the execution of strategic priorities.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Revenue Growth: Looking ahead to 2026, the company expects a more measured near-term growth profile for VYVGART influenced by pricing dynamics and evolving competition. ZEJULA is expected to experience some variability early in the year due to volume-based procurement dynamics and seasonality, but remains well positioned in the first-line setting. Full-year revenue for 2025 grew 15% year-over-year to $460 million.

Pipeline Catalysts: Several meaningful pipeline catalysts are expected in 2026, including clinical data for zoci in brain metastasis, neuroendocrine carcinoma, and first-line small cell lung cancer, as well as first-in-human data from the IL-13/IL-31 receptor bispecific program in atopic dermatitis.

Product Launches: The commercial launch of KarXT in schizophrenia is planned for the second quarter of 2026, with a focus on disciplined execution, building disease awareness, and establishing clinical confidence.

Regulatory Approvals: TIVDAK is expected to receive approval in China in the first half of 2026. Elegrobart is anticipated to report top-line data for the global registrational REVEAL-1 study in active TED in the first quarter of 2026, followed by results from the REVEAL-2 study in chronic TED in the second quarter of 2026. Povetacicept remains on track with an interim analysis for the global RAINIER Phase III study for IgAN planned for the first half of 2026.

Strategic Focus: 2026 is a year focused on execution and preparation, maintaining the strength and stability of the existing business while preparing for multiple growth opportunities ahead. Investments are being made across commercial and R&D to support a multiyear growth trajectory extending beyond 2026.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:Can you provide any color on how we should be thinking about revenues and expenses for 2026?

A:Management expects good growth opportunities for VYVGART and volume gains to continue in 2026. ZEJULA ended the year well, and while Lynparza faces a generic market, they aim to hold or grow their position. XACDURO is expected to be a driver, and launches of COBENFY and TIVDAK are anticipated to contribute to growth. SG&A expenses will see modest investments for launches, and R&D expenses are expected to remain relatively flat with some capacity freed up as late-phase opportunities in China come offline. 2026 is described as a transition year with moving pieces like VYVGART IV price adjustments and rebate dynamics.

Q:Can you remind us of the implications of the intracranial activity in patients with brain metastases for zoci?

A:Brain metastases are a significant issue, with 70% of patients developing them. Zoci has shown up to 80% response rates in untreated metastases and prevents recurrences in the brain. Management plans to report data using the stringent RANO criteria in the first half of the year.

Q:Can you elaborate on the U.S.-China development model and its impact on clinical derisking or timeline acceleration?

A:The model leverages efficient development structures and regulatory functions in China, allowing for speedy development and global trial participation. China is expected to enroll about 1/3 of patients in pivotal trials, such as the current second-line zoci trial. This efficiency has enabled rapid progression, like zoci moving to Phase III within two years of IND.

Q:What are the expectations for zoci data in neuroendocrine carcinoma (NEC) and its regulatory pathway?

A:Initial data in second-line NEC will be presented in the first half of the year, with about 60 patients included. Management is exploring whether a single-arm study would suffice for regulatory approval or if a randomized trial is needed. Discussions with regulators are ongoing.

Q:Does the company believe it could achieve breakeven or profitability by the end of the year?

A:Corporate profitability and cash flow breakeven remain clear objectives. Timing depends on top-line growth and investment levels in global programs. The company is commercially profitable and aims to remain efficient and disciplined in spending.

Q:What is the expectation for completion of enrollment and timing of reading out the primary endpoint for the global second/third-line DLL3 study?

A:The study started in December, with 75% of patients expected to be enrolled by year-end. Full enrollment is anticipated by the end of Q1 next year, with analysis and filing to follow. Approval is targeted for 2028.

Q:What is the strategy to grow VYVGART, specifically in increasing cycles per patient?

A:The focus is on achieving a minimum of 3 cycles per patient, leveraging updated national guidelines in China and affordability initiatives. Progress has been made, with a 50% improvement in average cycles in 2025 compared to 2024. Efforts include educating physicians, co-pay assistance programs, and expanding to non-acute patients.

Q:What is the regional breakdown of sites and patients for the global second/third-line DLL3 study?

A:About 30% of patients will come from China, 30% from the U.S., and the rest from Europe and other regions. The distribution ensures representation of real-world usage in the U.S. and other key markets.

Q:What are the plans for zoci in first-line small cell lung cancer and NEC?

A:For first-line small cell lung cancer, data from doublet and triplet regimens will be presented in the second half of the year, with a Phase III study planned to start by year-end. For NEC, management is exploring advancing to first-line treatment in the future.

Q:What should we expect from KarXT in 2026 and 2027?

A:KarXT will launch commercially in Q2 2026, focusing on physician education and initial patient use. NRDL listing is expected in 2027, unlocking significant financial value. The commercialization team will target 800 key institutions, with a team size of around 100. Financial impact in 2026 is expected to be minimal.

Q:What is the company’s strategy for business development, particularly in oncology and immunology?

A:The company is focused on late preclinical targets with biological precedence, leveraging clinical development expertise to introduce first and best-in-class products. Recent deals, like the MUC17 agreement, reflect this strategy.

Q:What are the potential risks of having tarlatamab as a post-progression treatment option in the second-line small cell lung cancer trial?

A:Management believes there is no significant bias risk, as tarlatamab will be used equally in both arms of the study. Patients are stratified for prior tarlatamab use, and post-progression therapies are expected to be balanced across arms.

Q:Review of Unclear Management Responses

A:Management avoided providing full-year guidance for 2026, citing moving pieces like VYVGART IV price adjustments, rebate dynamics, and hospital budgeting behavior. They stated they would share more specifics later in the year.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

ZLAB Transcript

Zai Lab Limited (ZLAB) Q4 2025 Earnings Call Transcript

Positive2-26

Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Neutral1-13

Zai Lab Limited (ZLAB) Q3 2025 Earnings Call Transcript

Positive11-7

The earnings call summary and Q&A indicate strong product development and strategic business updates, particularly in the pipeline and market expansion. Despite some challenges, such as supply constraints and competitive pressures, the company maintains a positive outlook with reaffirmed revenue guidance and expected profitability. The focus on AI, operational efficiency, and shareholder returns further supports a positive sentiment. Given the small-cap status, the stock is likely to react positively, but not overly so, hence a 'Positive' rating.

Zai Lab Limited (ZLAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Neutral9-9

ZLAB Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.